Akhil Santhosh

• A competent, patient oriented and academically meritorious medical oncologist with special aptitude in all solid tumors, hematological malignancies and supportive care
• I currently work as a consultant medical oncologist in the department of medical oncology, MVRCCRI, Calicut. My job profile includes seeing patients in the outpatient department, formulating their treatment plans, administering chemotherapy/targeted therapy/immunotherapy, assisting in clinical trials and management of inpatients. We have rotations in breast, lung, GI, sarcoma, Head-neck, Gynec-oncology and Hematology clinics

LIST OF AWARDS

• ASCO IDEA award 2025
• CAS GI ESO 2025
• Best research paper by senior resident: AIIMS Research-day 2024
• ASCO merit award winner 2023, abstract entitled “Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of Hand- foot syndrome in patients receiving capecitabine”, JCO, 2023
• Cleared the Speciality certificate examination Medical oncology conducted by the Royal College of Physicians UK London
• Topper in 2023 ESMO EXAM (ESMO talent pool)
• Batch topper (gold medal for best outgoing student- DM medical oncology 2023)
• ICMR travel grant for ASCO 2023
• ESMO GI Developing nations travel award 2023
• ASCO Breakthrough 2023 travel merit award
• ESMO 2023 world congress travel merit award
• Silver medal in Biochemistry (MBBS)
• Silver medal in General Medicine (MBBS)

LIST OF PUBLICATIONS

• Article "Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial" in JCO oncology (D-TORCH)
• Review article "Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps" in Drug design, Development and Therapy
• Poster presentation: "Treatment-Emergent Macrocytosis as a Biomarker of Response to First-Line Palbociclib in Hormone receptor +/HER2− Denovo Metastatic Breast Cancer: A Single-Centre Real-World Study" in ESMO Breast Congress 2026
• "Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW", correspondence in The Lancet
• Poster presentation: "Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India." ASCO 2025
• "Pre-transplantation optimisation for unresectable colorectal liver metastases; the TransMet trial", correspondence in The Lancet
• "Final overall survival results of checkmate 067", correspondence in NEJM
• "Doxorubicin-Trabectedin in Leiomyosarcoma", correspondence in NEJM
• Bold Brushstrokes, Bravery, and the Bat-Fan: The Girl Who Laughed in Color; Art of Oncology section in JCO GO Oncology
• Original study "Association of serum cyclooxygenase-2 levels with hand-foot syndrome in patients receiving capecitabine: an exploratory analysis of D-TORCH study" published in e cancer medical sciences
• Original study "DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study" published in Frontiers in Pharmacology
• Final Overall Survival Results of PRIMA: The Niraparib Conundrum, commentary published in IJMPO Journal
• Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late? commentary published in IJMPO Journal
• Short commentary "Checkpoint Dilemma: KEYNOTE-564’s Triumph Amidst the Failures of Its Rivals in Renal Cell Carcinoma? in Journal of Case Reports and Reviews in Medicine
• Poster presentation: “Real world study of dosing strategies of cabozantinib in metastatic renal cell carcinoma”, ESMO ASIA 2023 Singapore
• Manuscript entitled “SUCCINATE DEHYDROGENASE DEFICIENT GIST: CASE SERIES AND REVIEW OF LITERATURE FROM A TERTIARY CARE CENTRE IN INDIA”, presented in ESMO ASIA 2022 and published in Indian journal of cancer.
• Manuscript entitled “Metastatic sclerosing epithelioid fibrosarcoma in an adult male from a tertiary care centre in India”, E-cancer Medical Science Journal
• Research paper entitled “IS THERE AN OPTIMAL REGIMEN FOR DOUBLE HIT LYMPHOMAS?”, Cancer Research, Statistics and Treatment journal
• Research paper entitled “Is Fulvestrant the correct choice for early switch with rising ESR1 mutation?”, Cancer Research, Statistics and Treatment journal
• Research paper entitled “Is Hans algorithm outdated?”, Cancer Research, Statistics and Treatment journal
• Research protocol paper “Randomized double- blind, placebo-controlled study of topical Diclofenac in prevention of hand-foot syndrome in patients receiving Capecitabine “, TRIALS journal (BMC)
• Manuscript entitled “quality of life assessment in testicular non-seminomatous germ cell tumour survivors”, Research square journal
• Manuscript entitled “letter to editor- Rezvilutamide in metastatic hormone sensitive prostate cancer”, CRST journal
• Poster presentation “Topical diclofenac for prevention of hand foot syndrome in GI cancers- an exploratory subgroup analysis of the D Torch study”, ESMO GI conference 2023
• Poster presentation “Topical diclofenac for prevention of hand foot syndrome in Breast cancers- an exploratory subgroup analysis of the D torch study”, ASCO Breakthrough conference 2023
• Oral presentation “serum-cox 2 levels as a biomarker for capecitabine related hand foot syndrome “, World congress on cancer research and therapy, Frankfurt, 2023
• Case report entitled “ Burtons line- a unique sign of Lead poisoning “, World journal of Gastroenterology
• Randomized control trial of Levetiracetam vs Carbamazepine for seizures in patients with Neurocysticercosis”, Acta Neurologica Scandinavica
• A Rare Case of a Malignant Epithelioid Neoplasm with an Underlying novel EWSR1:ZBT44 Fusion, Identified on Next-Generation Sequencing (NGS), International Journal of Surgical Pathology April 2024

• Conducted patient assessments and developed individualized care plans.
• Collaborated with multidisciplinary teams to ensure comprehensive patient care.
• Supervised junior residents and provided mentorship during clinical rotations.
• Assisted in research studies by collecting and analyzing patient data.